Receptos jumps on Phase II MS data

Receptos Inc. (NASDAQ:RCPT) gained $11.20 (38%) to $40.40 in early after-hours trading on Monday after reporting RPC1063 met the primary endpoint in the Phase II portion of the Phase II/III RADIANCE trial to treat relapsing multiple sclerosis (MS). Both 0.5 and 1 mg oral once-daily doses of RPC1063 reduced the cumulative number of total gadolinium-enhancing lesions as determined by MRI by 86% from week 12 to week 24 vs. placebo (p<0.0001 for both).

Receptos said there was a positive trend for both RPC1063 arms compared to placebo in reducing annualized relapse rate (ARR), although the 258-patient Phase II portion was not powered to detect a significant difference on that endpoint. ...